Patents Assigned to AGIOS PHARMACEUTICALS, INC
  • Combination therapy for treating malignancies
    Patent number: 10905692
    Abstract: Provided are methods and compositions for treating AML in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and an AML induction and consolidation therapy.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: February 2, 2021
    Assignee: Agios Pharmaceuticals, Inc.
    Inventor: Samuel V. Agresta
  • Pharmaceutical compositions of therapeutically active compounds
    Patent number: 10799490
    Abstract: Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: October 13, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventor: Chong-Hui Gu
  • Inhibitors of cellular metabolic processes
    Patent number: 10800782
    Abstract: The present disclosure provides MAT2A inhibitor compounds that are useful as therapeutic agents for treating malignancies, and wherein the compounds conform to general formula (IA): wherein RA, RB, RC, RD, and RE are defined herein.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: October 13, 2020
    Assignee: Agios Pharmaceutical, Inc.
    Inventors: Zenon D. Konteatis, Zhihua Sui, Jeremy M. Travins, Zhixiong Ye
  • Methods of treating brain tumors using combination therapy
    Patent number: 10780093
    Abstract: Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: September 22, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Joshua Murtie, Nelamangala Nagaraja, Brandon Nicolay, David Schenkein, Katharine Yen
  • Therapeutically active compounds and their methods of use
    Patent number: 10730854
    Abstract: Provided are compounds useful for treating of cancer and methods for treating of cancer, comprising administering to a subject in need thereof a compound described therein.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: August 4, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Samuel V. Agresta, Chong-Hui Gu, David Schenkein, Hua Yang, Liting Guo, Zhen Tang, Jianming Wang, Yanfeng Zhang, Yan Zhou
  • Therapeutically active compounds and their methods of use
    Patent number: 10717764
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: July 21, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Janeta Popovici-Muller, Rene M. Lemieux, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Methods for diagnosing IDH-mutant cell proliferation disorders
    Patent number: 10711314
    Abstract: Methods of diagnosing subjects having a cell proliferation-related disorder or suspected of having a cell proliferation-related disorder associated with mutant IDH enzymes with 2HG neoactivity.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: July 14, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Leonard Luan C. Dang, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Shin-San Michael Su, Craig Thompson
  • PYRUVATE KINASE MODULATORS AND USE THEREOF
    Publication number: 20200206225
    Abstract: Described herein are methods of using compounds of Formula (I) to modulate PKM2 activity in a subject. These compounds are represented by Formula (I): wherein R1, R2, L1, and L2 are as defined herein.
    Type: Application
    Filed: August 15, 2018
    Publication date: July 2, 2020
    Applicant: Agios Pharmaceuticals, Inc.
    Inventors: Giovanni Cianchetta, Charles Kung, Tao Liu, Anil Kumar Padyana, Zhihua Sui, Zhenwei Cai, Dawei Cui, Jingjing Ji
  • Combination therapy for treating malignancies
    Patent number: 10695352
    Abstract: Provided are methods and compositions for treating cancers in patients carrying an IDH2 mutation using a combination of an inhibitor of a mutant IDH2 enzyme and a DNA demethylating agent.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: June 30, 2020
    Assignees: Celgene Corporation, Agios Pharmaceuticals, Inc.
    Inventors: Vivek Saroj Kumar Chopra, Jorge DiMartino, Laurie A. Kenvin, Robert Douglas Knight, Kyle MacBeth, Krishnan Viswanadhan, Qiang Xu, Samuel V. Agresta
  • Compounds and their methods of use
    Patent number: 10689375
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: June 23, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Yongsheng Chen
  • Therapeutically active compounds and their methods of use
    Patent number: 10689414
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 23, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Combination therapy for treating malignancies
    Patent number: 10653710
    Abstract: Provided are methods and compositions for treating hematological malignancies in patients carrying an IDH1 mutation using a combination of an inhibitor of mutant IDH1 enzyme, (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide, or a pharmaceutically acceptable salt thereof (COMPOUND 2) and a DNA demethylating agent.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 19, 2020
    Assignees: Agios Pharmaceuticals, Inc., Celgene Corporation
    Inventors: Samuel V. Agresta, Krishnan Viswanadhan, Jorge DiMartino, Vivek Saroj Kumar Chopra, Kyle J. MacBeth, Robert Douglas Knight, Laurie Kenvin, Qiang Xu
  • Therapeutically active compositions and their methods of use
    Patent number: 10640534
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: May 5, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Janeta Popovici-Muller, Rene M. Lemieux, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Pyruvate kinase activators for use in therapy
    Patent number: 10632114
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 28, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Shin-San Michael Su, Lenny Dang
  • Methods and compositions for cell-proliferation-related disorders
    Patent number: 10610125
    Abstract: Methods of treating and evaluating subjects having neoactive mutants are described herein.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: April 7, 2020
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Lenny Dang, Valeria Fantin, Stefan Gross, Hyun Gyung Jang, Shengfang Jin, Francesco G. Salituro, Jeffrey O. Saunders, Shin-San Michael Su, Katharine Yen
  • METHODS OF USING PYRUVATE KINASE ACTIVATORS
    Publication number: 20200030322
    Abstract: Described herein are methods for using compounds that activate pyruvate kinase.
    Type: Application
    Filed: June 10, 2016
    Publication date: January 30, 2020
    Applicant: Agios Pharmaceuticals, Inc.
    Inventors: Samuel V. Agresta, Yue Chen, Marvin B. Cohen, Lenny Dang, Charles Kung, Elizabeth A. Merica, Bruce A. Silver, Hua Yang
  • Pharmaceutical compositions of therapeutically active compounds
    Patent number: 10449184
    Abstract: Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: October 22, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventor: Chong-Hui Gu
  • Therapeutically active compounds and their methods of use
    Patent number: 10434105
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: October 8, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventor: Stefan Kluge
  • Glutaminase inhibitors and method of use
    Patent number: 10414740
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: September 17, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan
  • 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
    Patent number: 10376510
    Abstract: Provided are compounds of formula (I), wherein: ring A and ring B are each independently an optionally substituted 5-6 membered monocyclic aryl or heteroaryl; one of X, Y and W is CH and the two others are N; and Z is H or —C(R1)(R2)(R3). The compounds are inhibitors of isocitrate dehydronenase 2 (IDH2) mutants useful for treating cancer.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: August 13, 2019
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Zenon D. Konteatis, Janeta Popovici-Muller, Jeremy M. Travins